Lenvazee 10 mg contains Lenvatinib, a multi-targeted tyrosine kinase inhibitor (TKI) designed to block key receptors responsible for cancer cell proliferation and blood vessel formation. It plays an important role in modern targeted oncology therapy.

🔬 Mechanism of Action

Lenvatinib inhibits several receptor tyrosine kinases including:

• VEGFR (Vascular Endothelial Growth Factor Receptors)
• FGFR (Fibroblast Growth Factor Receptors)
• PDGFR, RET, and KIT

As a result, it reduces tumor angiogenesis and slows cancer cell growth, helping delay disease progression.

💊 Indications

Lenvazee 10 mg is indicated for:

• Radioactive iodine-refractory differentiated thyroid cancer (DTC)
• Unresectable hepatocellular carcinoma (HCC)
• Advanced renal cell carcinoma (RCC) (in combination therapy)
• Advanced endometrial carcinoma (in combination therapy)

📌 Key Features of Lenvazee 10 mg

• Strength: 4 mg and 10 mg
• Dosage Form: Oral capsule
• Therapeutic Class: Multi-targeted Tyrosine Kinase Inhibitor
• Administration: Taken orally once daily; total daily dose may vary depending on indication
• Monitoring: Blood pressure, liver function, thyroid function, renal function, and proteinuria monitoring required

⚕️ Benefits of Lenvatinib

• Broad-spectrum targeted therapy
• Oral administration for patient convenience
• Effective in multiple advanced cancers
• Helps control tumor progression

⚠️ Precautions

• May cause hypertension, diarrhea, fatigue, and decreased appetite
• Risk of proteinuria and liver dysfunction
• Dose adjustments may be required based on tolerance
• Regular monitoring essential during therapy
• Use strictly under oncologist supervision

Lenvazee 4 mg (Lenvatinib Capsules) offers an effective targeted treatment option for advanced cancers, supporting improved disease control and patient outcomes when administered under specialized medical guidance.